Phyllodes tumour of the breast: the decisions you may face
4 treatment settings, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Diagnosis
Ultrasound and mammography, core needle biopsy, and excision of any rapidly growing or large fibroepithelial lesion because biopsy cannot reliably separate phyllodes tumour from fibroadenoma.
Ultrasound uses sound waves to make live pictures; it is cheap, safe, and used to guide needles into lumps.
- Real-time, portable, no radiation
- Ideal biopsy guidance
Low-dose breast X-ray used for screening. Newer 3D versions find more cancers with fewer false alarms.
- Proven mortality benefit
- Cheap and scalable
Histopathology means looking at cancer cells under a microscope, and immunohistochemistry stains them for specific proteins. Together they are still the foundation of every diagnosis.
- Cheap, fast, universal
- Companion diagnostic for most targeted drugs
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Operator dependent
- Cannot see through bone or air
- Reduced sensitivity in dense breasts
- Overdiagnosis of indolent lesions
- Subjective scoring
- Single-site sampling misses heterogeneity
- Between Ultrasound, Mammography & tomosynthesis and Histopathology & immunohistochemistry, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (diagnosis), which of the standard options do you recommend and why?Why: Guideline options include: Ultrasound and mammography, core needle biopsy, and excision of any rapidly growing or large fibroepithelial lesion because biopsy cannot reliably separate phyllodes tumour from fibroadenoma.
Add these to your appointment list, or take the full question set for this cancer.
Benign phyllodes tumour
Complete excision with clear margins; observation if margins are close after a benign diagnosis.
This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
- Which specific treatments are you proposing for this setting, and what are the alternatives?Why: The standard of care here is described in words rather than named products; ask for the names.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (benign phyllodes tumour), which of the standard options do you recommend and why?Why: Guideline options include: Complete excision with clear margins; observation if margins are close after a benign diagnosis.
Add these to your appointment list, or take the full question set for this cancer.
Borderline and malignant phyllodes tumour
Wide excision aiming for clear margins or mastectomy for large tumours, no axillary staging, and adjuvant radiotherapy considered after breast conservation.
IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.
- Conformal dose, fewer side effects
- Hypofractionation saves visits
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Low-dose bath to normal tissue
- Motion management
- Is IMRT / IGRT (modern external beam) the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?Why: A single standard does not mean a single choice; timing and trials are decisions too.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (borderline and malignant phyllodes tumour), which of the standard options do you recommend and why?Why: Guideline options include: Wide excision aiming for clear margins or mastectomy for large tumours, no axillary staging, and adjuvant radiotherapy considered after breast conservation.
Add these to your appointment list, or take the full question set for this cancer.
Metastatic malignant phyllodes tumour
Treated as a soft-tissue sarcoma with doxorubicin-based chemotherapy; no proven benefit from adjuvant chemotherapy.
The red chemotherapy drug from a soil bacterium that is still the backbone of treatment for sarcoma, lymphoma and breast cancer, limited by cumulative heart damage.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Cumulative dose: risk rises steeply above 400-550 mg/m² (see the anthracycline calculator).
- Reduce by 50% for bilirubin 20-50 µmol/L and 75% for 50-85 µmol/L.
- Is Doxorubicin the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?Why: A single standard does not mean a single choice; timing and trials are decisions too.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (metastatic malignant phyllodes tumour), which of the standard options do you recommend and why?Why: Guideline options include: Treated as a soft-tissue sarcoma with doxorubicin-based chemotherapy; no proven benefit from adjuvant chemotherapy.
- Am I a candidate for Doxorubicin, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.